Peach Medical Secures Tens of Millions in Series A Led by Matrix Partners China; Human Longevity Raises $220M in Series B

VCBeat Weekly Investment and Financing News Report，April 4–10, This WeekThe total financing amount raised by the domestic and international digital health sectors exceeded$275 million.

It is reported that the major financing event in China's internet healthcare industry this week was Peijia Medical’s Series A funding round, which secured tens of millions of US dollars and was led by Matrix Partners China. Meanwhile, abroad, Illumina led a significant $220 million Series B financing round for the genetic testing company Human Longevity, drawing considerable attention to the underlying reasons.

Analysis of Hot Financing Projects in China



This Week's Hot Financing Project: Peijia Medical

▪Peijia Medical—whose main products areInterventional Heart Valvesa high-end medical device R&D company, with Matrix Partners China bullish on its team’s scientific research capabilities

Peijia Medical is a high-tech enterprise dedicated to the research and development, manufacturing, and sales of premium medical devices for the treatment of structural heart disease. The company has positioned its entrepreneurial focus on the interventional cardiac valve sector, which remained an untapped market in China. Boasting strong R&D capabilities, Peijia Medical holds four invention patents in the field of “prosthetic heart valves.” This innovative technology can significantly improve survival rates for patients with heart disease. On March 29, 2016, Peijia Medical announced that it had secured tens of millions of U.S. dollars in Series A financing, led by Matrix Partners China. Yu Zhiyun, Investment Director at Matrix Medical, stated that they were impressed by the founding team’s outstanding track record in the domestic interventional cardiac device sector, as well as the company’s confidence, determination, and scientific research capabilities to fill the market gap in interventional cardiac valves in China.

Companies whose products and services are industry leaders

▪ Ma Long Dental —1993Established inLisbon, Portugal, the company’s products and services are industry leaders

Founded in Lisbon, Portugal, in 1993 by Dr. Paulo Malo, a globally renowned master in dental implantology and prosthodontics, the Malo Clinic officially entered the Chinese market in 2013. As a technology-driven international professional dental chain, Malo Clinic ranks among the world’s leaders in dentistry, with over 19 years of experience in the field. Its core competitive advantages lie in its comprehensive global human resources system, strong differentiated technological capabilities, and a unique patient referral network. Recently, Malo Clinic China announced the completion of an RMB 85 million Series B financing round, led by GGV Capital.

A Company That Has Obtained Two Software Copyrights

▪365 Hospital Network—Two software products developed by the team hold copyright registration, and the company is dedicated to developing a telemedicine information service platform.

365 Hospital Network, a subsidiary of Yijia Hulian (Wuhan) Information Technology Co., Ltd., is a telemedicine information service platform centered on primary healthcare institutions. On this platform, each primary hospital can establish its own ecosystem, featuring specialists, hospital physicians, and the hospital’s own operational workflows. Currently, 365 Hospital Network has obtained two software copyrights. Today, 365 Hospital Network announced that it has secured an angel round of financing amounting to nearly RMB 10 million. This round was led by the Puhua Jingxin Guzhou Health Industry Fund, a new fund under Puhua Capital focused on the broader health industry.



Analysis of Hot Overseas Financing Projects



Projects with High Attention This Week

▪Human LongevityCompany—Dedicated to leveraging genetic testing to help extend human lifespan,Secures $220 Million in Series B Financing

Human Longevity, Inc. was founded in 2014 by J. Craig Venter, a pioneer in the field of genomics. To date, the company has analyzed and studied the genomic sequences of more than 20,000 individuals. In addition to collecting whole-genome sequences, the company also gathers genetic data on trillions of microorganisms inhabiting the human body, both internally and externally, while simultaneously compiling and organizing metabolomics-related data. The company raised $220 million in its Series B financing round. This substantial funding was secured because the company was established during a period of explosive growth in new technologies, characterized by a sharp decline in genome sequencing costs, rapid advancements in bandwidth, and the emergence of cloud computing and machine learning technologies—all of which facilitated the project’s development. Investors in this round included Illumina, Celgene, and GE Ventures.

Companies Integrating Confidentiality Technology into Projects

▪ CrossChx – Dedicated to the R&D of patient check-in kiosks, its solutions have significantly reduced patient waiting times.

CrossChx, a company based in Ohio, USA, specializes in the development of auxiliary patient registration devices. Its “Queue” product series includes a multi-touch tablet and a 42-inch LCD digital kiosk for patient guidance. After entering their personal information, patients can access their medical records at other hospitals equipped with these devices using fingerprint authentication. The kiosk displays the number of people ahead in line, the estimated waiting time, and guides users to designated locations to complete registration, significantly reducing patient wait times. Fingerprint authentication enhances the confidentiality of personal information, and over 50 million patients have already created accounts on the Queue platform. Recently, the company announced that it had secured $15 million in Series C financing. This round was jointly invested by Silicon Valley Bank, Khosla Ventures, Drive Capital, NCT Ventures, and Moonshots Capital. To date, the company has raised a total of $35 million.

Company Supported by Big Data Technology

▪ Sweetch – The project leverages big data for diabetes risk prediction and is likely to secure its next round of financing in the near future.

Sweetch, an Israel-based company, specializes in the development of software for predicting diabetes risk. This software not only estimates the likelihood of developing the disease in at-risk individuals but also helps undiagnosed patients become aware of their condition. By analyzing user-inputted data through big data analytics, the software assesses users’ disease risk and provides lifestyle recommendations. A medical center currently establishing a digital health accelerator program has stated that it will prioritize investment in Sweetch among numerous projects. The company is actively seeking patent protection for this software. Recently, Sweetch secured $3.5 million in its Series A financing round, led by the crowdfunding platform OurCrowd.

For the latest and hottest financing news in the domestic and international internet healthcare sector, please continue to follow VCBeat.。

Text | Deng Xueyuan